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ABSTRACT
Bacteriophagelambda(l)permitsthedisplayofmany
foreign peptides and proteins on the gpD major coat
protein. However, some recombinant derivatives of
gpD are incompatible with the assembly of stable
phage particles. This presents a limitation to current
ldisplaysystems.Herewedescribeanovel,plasmid-
based expression system in which gpD deficient
l lysogens can be co-complemented with both wild-
typeandrecombinantformsofgpD.Thisdualexpres-
sion system permits the generation of mosaic phage
particles that contain otherwise recalcitrant recom-
binant gpD fusion proteins. Overall, this improved
gpD display system is expected to permit the expres-
sion of a wide variety of peptides and proteins on the
surface of bacteriophage l and to facilitate the use of
modifiedlphagevectorsinmammaliangenetransfer
applications.
INTRODUCTION
Bacteriophage l is a temperate phage with a double-stranded
(ds) genome of  48 kb encapsulated in an icosahedral capsid
( 50 nm in diameter) with a long and ﬁbrous tail ( 150 nm in
length). The l capsid is composed of two major coat proteins,
gpE and gpD. Lambda capsid maturation begins with the
formation of the prohead, composed solely of gpE (1). As
the genomic DNA is packaged, the capsid expands in volume
by  45% and  405 copies of gpD are then added to fully
populate and stabilize the capsid (2).
gpD is a 109 amino acid protein (excluding the initial
methionine which is removed from the mature protein) (3)
and is required for the packaging of full-length genomes (4).
gpD-deﬁcient l mutants with genome sizes between 78–82%
of wild-type are viable, although they are highly unstable in
the presence of chelating agents such as EDTA. EDTA is
thought to remove essential Mg
2+ ions that serve to neutralize
the negative charges associated with the phosphate backbone
of the phage genome (2,4,5).
The discovery thatforeign peptidesor protein fragments can
be displayed on the surface of ﬁlamentous bacteriophage (6,7)
has led to the development of phage display technology, with
applications that include antibacterial therapy, antibody
discovery, cDNA screening and display and gene delivery
to mammalian cells (8–40). Our laboratory is particularly
interested in protein display on bacteriophage l, since we
believe that l may have certain advantages over ﬁlamentous
phages in gene transfer applications. These include the
physical properties of l phage, which is more similar in
size and shape to mammalian viruses than M13, and the
size and nature of the l genome, which has a large dsDNA
molecule versus the smaller single-stranded (ss) DNA genome
of M13 (21).
Bacteriophage l has been shown to be able to accommodate
the display of foreign peptides and proteins on the gpD major
coat protein (3,4,15,20,28,35,38). However, in the course of
our studies, we have encountered certain proteins that are
poorly tolerated when displayed on the bacteriophage l capsid
at high copy number (405–420 copies per capsid), resulting in
an inability to generate recombinant phage particles that
display the desired molecule. To solve this problem, we
developed a novel dual expression system in which gpD deﬁ-
cient lysogens can be complemented with both wild-type gpD
protein and gpD-fusion coat proteins—thereby generating
mosaic phage particles that contain both wild-type and
recombinant versions of gpD. In the present work, we
demonstrate the application of this technology to the surface
display of a genetically engineered derivative of the tenth
ﬁbronectin type III domain (3JCLI4), which has nanomolar
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doi:10.1093/nar/gni158afﬁnity for the cellular avb3 integrin receptor (41). The results
show that the newly developed gpD co-expression system can
permit the effﬁcient display of an otherwise poorly tolerated
protein on the surface of bacteriophage l. This methodology is
expected to prove usefulinthe future development of modiﬁed
l phage recombinants, including constructs that may have
utility in human gene transfer applications.
MATERIALS AND METHODS
Lambda D1180 (Luc) lysogens
Lambda D1180 (Luc) lysogens were provided as a kind gift
from Dr Mahito Nakanishi and DNAVEC Corp. (15); these
phage genomes contain a mammalian expression cassette that
encodes for ﬁreﬂy luciferase under the transcriptional
control of the human cytomegalovirus (CMV) immediate
early promoter.
pTrc-gpD expression plasmids
An Escherichia coli codon-optimized derivative of the wild-
type l gpD gene was generated synthetically (GeneArt,
Regensburg, Germany) and inserted into the pTrcHis plasmid
(Invitrogen). The optimized sequence was selected on the
basis of Entelechon’s proprietary gene design software
(http://www.entelechon.com/), which performs codon optim-
ization for the species of interest, while avoiding speciﬁed
restriction enzyme sites. The corresponding sequence is avail-
able via GenBank, with the accession no. DQ156943.
Theresultingconstruct,pTrc-gpD-fusion containedthecodon-
optimized gpD sequence (with its authentic ATG codon, but
without a translational stop codon), followed by a short ﬂex-
ible linker sequence [G(SGGG)2SGGT] and then by BamHI
and KpnI restriction sites; desired fusion partners of interest
were inserted between the KpnI site and a terminal HindIII
site. Note that, during the process of cloning, the native,
promoter-proximal NcoI site within pTrc was eliminated.
In order to derive a construct that expressed gpD alone, the
gpD insert was subjected to PCR ampliﬁcation using primers
that added a translational stop codon at the 30 end of the gpD
gene. The oligonucleotide primers used for this ampliﬁcation
were: (i) gpD-StopFOR (50-aagctttcATGaccagcaag-30) and
(ii) gpD-StopREV (50-atctaagcttCTAtacaatactgattgcggtg-30);
underlined sequences denote the added BspHI and HindIII
sites, respectively, while capitalized boldface letters denote
the ATG codon and inserted translational stop codon, respect-
ively. The resulting PCR product was restricted with BspHI
and HindIII and then inserted into the parental pTrc vector
using the NcoI and HindIII restriction sites, to create
pTrc-gpD.
We next created a series of plasmid constructs in which
speciﬁc sequences of interest were fused to gpD. The exogen-
ous DNA sequences that we chose to add included an insert
encoding for a high-afﬁnity avb3 binding protein derived
from the tenth ﬁbronectin type III domain (3JCLI4) (41).
This was PCR ampliﬁed from an available parental plasmid
(41), using the following primers: 3JCLI4FOR (50-atcggtacc-
caggtttctgatgttccgcgt-30) and 3JCLI4REV (50-ggccaagctt-
CTAggtacggtagttaatcg-30). The PCR product was then
digested with KpnI and HindIII (these sites are underlined
in the primer sequences) and inserted into the corresponding
restriction sites of our pTrc-gpD-fusion vector, so as to create
pTrc-gpD-3JCLI4.
In order to create plasmid vectors that permit expression of
twodifferent forms ofgpD within the same E.colihost cell, the
pBR322-derived pMB1 origin of DNA replication in the pTrc-
based expression plasmids [ 20 copies/chromosome equival-
ent; (42,43)] was replaced with a compatible origin of DNA
replication derived from the CloDF13 replicon [ 20–40
copies/chromosome equivalent; (44,45)]. The CDF-derived
originand ﬂankingantibiotic resistancemarker were ampliﬁed
by PCR from the pCDF-1b plasmid (Novagen), using
CDFDUETFOR (50-agctccatgggaagcacacggtcacactgct-30) and
CDFDUETREV (50-agctgcatgcaagttagctcactcattaggga-30),
digested with SphI and NcoI (these sites are underlined in
the primer sequences), and then inserted into the SphI and
BspHI sites in pTrc and its derivatives. All gpD-encoding
plasmids containing the pBR322 or CDF origins of replication
alsocarry the ampicillin or spectinomycin antibiotic resistance
genes, respectively.
Preparation of gpD-mosaic phage
Lysogens of TOP10 cells (Invitrogen) containing l D1180
(Luc) (15) were transformed with pTrc plasmids encoding
either wild-type gpD alone or gpD-3JCLI4 alone or the
combination of wild-type gpD plus gpD-3JCLI4. Lysogens
containing the coat protein plasmids were grown to mid-log
phase at 32 C in the presence of antibiotics (ampicillin or
spectinomycin, 50 mg/ml, Sigma). The lysogens, which
contain a temperature-sensitive mutation in the cI repressor,
were then induced by increasing the culture temperature to
45 C for  15 min. After induction, cultures were incubated at
38 C for an additional 3 h to allow for phage replication and
assembly. Cells were then collected by centrifugation and
lysed with chloroform (Sigma). DNAse I (Worthington Bio-
chemicalCorp.) was added toa ﬁnal concentrationof10 mg/ml
to remove any contaminating nucleic acids, and lysed cultures
were cleared of debris by centrifugation; phage were pelleted
from the supernatant by ultracentrifugation. The resulting pel-
let was resuspended in phage suspension media [100 mM
NaCl, 10 mM MgSO4, 50 mM Tris–HCl (pH 7.5) and 0.1%
gelatin] and further puriﬁed by cesium chloride density gra-
dient ultracentrifugation. The resulting phage bands were
pulled from the gradient using a syringe and 18G needle
and dialyzed against 10 mM NaCl, 50 mM Tris–HCl (pH 7.5)
and 10 mM MgCl2. Phage preparations were titered on LE392
(supE, supF) E.coli host cells (Stratagene).
Production of polyclonal antiserum to gpD
The authentic (non-codon-optimized) l phage gpD gene was
ampliﬁed by PCR from pAT101 (kindly provided by
Dr Andreas Plu ¨ckthun and Dr Patrick Forrer, University of
Zurich, Switzerland) (3,46) using the gpD forward primer (50-
ggtgcccatatggcgagcaaagaaacctttacc-30) and the gpD reverse
primer (50-ccgacgggatcctcattaaacgatgctgattgc-30) and then
cloned into the pET15b plasmid (Novagen) using the NdeI
and BamHI restriction sites (underlined). The resulting
pET15b-gpD plasmid was transformed into BL21 cells
(Invitrogen). Transformed bacteria were grown to mid-log
phase and then induced for 3 h with isopropyl-b-D-
thiogalactopyranoside (IPTG) added to a ﬁnal concentration
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BugBuster (Novagen), and treated with benzonase and lyso-
zyme (Novagen) according to the manufacturer’s recom-
mendations. The resulting lysate was clariﬁed by
centrifugation and temporarily stored at  20 C. Thawed
lysate was puriﬁed using a Co
2+ column (BD Talon) according
to the manufacturer’s recommendations. The eluted fractions
were analyzed by PAGE, followed by immunoblot analysis
using an anti-His5 antibody reactive with the His6-tag that had
been added to the gpD protein. Approximately 3 mg of PAGE
puriﬁed gpD protein was used to raise a polyclonal antiserum
in rabbits (Sigma Genosys). The reactivity of the resulting
antiserumagainstgpDwasconﬁrmedbyimmunoblotanalysis,
and the antiserum was then preserved in 0.02% sodium mer-
thiolate and stored in aliquots at  80 C until use.
Immunoblot analysis of purified phage particles
A total of 1 · 10
9 plaque forming units (PFU) of CsCl-
banded phage particles were combined with 2· SDS load-
ing buffer and heated to 95 C for 5 min. Samples were
separated on a 20% SDS–PAGE gel. Proteins were then trans-
ferred to a nitrocellulose membrane and incubated with the
polyclonal anti-gpD anti-serum at a dilution of 1:1000 (in 1·
phosphate-buffered saline (PBS)/0.1% Tween (PBST) con-
taining 5% non-fat dry milk). After washing with PBST,
the nitrocellulose membrane was incubated with horseradish
peroxidase (HRP)-conjugated donkey anti-rabbit antibody
(Amersham) at a dilution of 1:3000 (also in PBST containing
5% nonfat dry milk). HRP-conjugated antibody was detected
using ECL-Plus substrate (Amersham). Blots were imaged
using the ChemiDoc XRS chemiluminescence chamber and
Quantity One software version 4.5.2 (BioRad).
RESULTS
Construction of gpD expression plasmids
In order to generate plasmids capable of efﬁciently expressing
gpD in E.coli host cells, we elected to synthesize an E.coli
codon-optimized (ECO) derivative of the wild-type l gpD
gene. We reasoned that codon optimization might lead to
more efﬁcient protein expression, as has been shown in
other systems (47). In addition, the E.coli codon-optimized
gene also has greatly reduced homology to its native l
counterpart (only 78% nucleotide identity). We anticipated
that this would effectively eliminate the potential for homo-
logous DNA recombination between the ECO-gpD sequence
and its native l phage counterpart—thereby reducing the pos-
sibility that a complementing gpD plasmid might recombine
with a gpD-deﬁcient l lysogen.
The ECO-gpD gene was inserted into pTrc to create pTrc-
gpD (Figure 1A), and a sequence cassette corresponding to the
Figure 1. gpD Expressionconstructs. Plasmidvectors forprokaryotic expressionof wild-typeand recombinant forms of gpD are shown.(A) An ECOderivative of
gpD(blue)wasinsertedintoanampicillin-selectable,pBR322-basedpTrcexpressionplasmid,whereitwasplacedunderthetranscriptionalcontrolofthehigh-level,
regulatableTrcpromoter(lightblue).(B)Asequencecodingforahigh-affinityavb3bindingproteinderivedfromthetenthfibronectintypeIIIdomain(3JCLI4;dark
blue) was inserted at the 30 end of the gpD insert in the plasmid shown in (A), resulting in the generation of a construct that encoded a gpD-3JCLI4 fusion protein.
(C) A matched dual expression plasmid set, capable of co-expressing wild-type gpD and the gpD-3JCLI4 fusion protein is shown. The ampicillin selection marker
(darkgreen)andpBR322-derived(darkred)originofreplicationintheplasmidshownin(A)werereplacedwithaspectinomycinresistancegene(lightgreen)anda
pCDF1-derivedoriginofreplication(lightred),togeneratethegpD-encodingplasmidshownontheleft.(D)Asecondmatcheddualexpressionplasmidset,capable
ofco-expressingwild-typegpDandthegpD-3JCLI4fusionproteinisshown.Inthiscase,theampicillinselectionmarkerandpBR322-derivedoriginofreplicationin
the plasmid shown in (B) were replaced with a spectinomycin resistance gene and a pCDF1-derived origin of replication, to generate the gpD-3JCLI4-encoding
plasmid shown on the right.
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terminal fusion to gpD, to create pTrc-gpD-3JCLI4
(Figure 1B). Additionally, constructs were generated in
which the pBR322 origin of replication in the pTrc-based
vectors was replaced with the CDF origin of replication, to
yield pTrc-gpD-CDF (Figure 1C) and pTrc-gpD-3JCLI4-CDF
(Figure 1D). Protein expression from each of these constructs
was conﬁrmed by immunoblot analysis of IPTG-induced bac-
terial cell lysates using a gpD-speciﬁc rabbit antiserum (data
notshown);theconstructswerethentransformedintolD1180
lysogens, in order to examine their ability to complement this
gpD-deﬁcient phage strain and thereby permit recovery of
infectious phage particles.
Co-expression of wild-type and recombinant gpD
permits surface display of otherwise recalcitrant
fusion proteins
Lysogens of TOP10 cells containing l D1180 (Luc) were
transformed with either the pTrc-gpD-3JCLI4 or pTrc-gpD
expression plasmid, encoding the gpD-3JCLI4 fusion protein
or wild-type gpD, respectively. Following heat induction, cell
lysis and cesium chloride density gradient ultracentrifugation
of a 1 l preparation, no phage particles could be recovered
from the lysogens that had been transformed with the plasmid
vector encoding the recombinant gpD-3JCLI4 coat protein
fusion—as reﬂected by the absence of the characteristic
l phage band in the cesium chloride density gradient
(Figure 2B). In contrast, when the l D1180 (Luc) lysogens
were transformed with a plasmid encoding wild-type gpD,
infectious phage particles were readily recovered (Figure 2A).
These results suggested that the gpD-3JCLI4 fusion protein
may eitherinterfere withphage assembly orpreventtheforma-
tion of stable phage particles. In considering how we might
resolve this unexpected difﬁculty, we decided to try to express
the gpD-3JCLI4 fusion protein on the surface of phage l
through the use of a mosaic approach, in which the ﬁnal virion
would contain a mixture of both wild-type and recombinant
gpD subunits.
Lysogens of TOP10 cells containing l D1180 (Luc) were
co-transformed with plasmids encoding both recombinant and
wild-type forms of gpD. This was achieved using a set of gpD
expression vectors that contained one of two origins of
replication—either the pBR322-derived pMB1 origin (pBR-
ori) or a second compatible, low-copy origin derived from
pCDF-1b (CDF-ori). Lysogens were then cotransformed
with either (i) a pBR-ori based plasmid encoding a recombin-
ant form of gpD (pTrc-gpD-3JCLI4) plus a CDF-ori based
plasmid encoding wild-type gpD (pTrc-gpD-CDF), or (ii) a
CDF-ori based plasmid encoding a recombinant form of gpD
(pTrc-gpD-3JCLI4-CDF) plus a pBR-ori based plasmid
encodingwild-typegpD(pTrc-gpD).Followingheat induction
of the lysogen, cell lysis, and cesium chloride density gradient
ultracentrifugation, we were able to efﬁciently recover phage
containing the gpD-3JCLI4 fusion protein that had previously
proven recalcitrant—as reﬂected by the presence of a charac-
teristic phage band in the CsCl gradient (Figure 2C and D).
These recombinant phage preparations were collected from
the CsCl gradient, dialyzed, and titered on LE392 E.coli host
cells. All of the phage preparations, including the mosaic
phages were found to be infectious (Figure 3). The titers
of the mosaic phages were generally similar to those of
Figure 2. Co-expression of 3JCLI4-gpD and wild-type gpD yields intact phage particles. Lysogens of TOP10 cells containing gpD-deficient l D1180 (Luc) were
transformedwithsingleplasmidvectorsencodingeitherwild-typegpD(gpD;seeFigure1A)ortherecombinantgpD-3JCLI4fusionprotein(3JCLI4;seeFigure1B).
Alternatively, the cells were co-transformed with two plasmids, corresponding to the constructs shown in Figure 1C (3JCLI4 DUAL) or Figure 1D (CDF3JCLI4
DUAL); these paired constructs permitted the co-expression of wild-type and recombinant gpD in the same E.coli host cell. Following lysogen induction and cell
lysis,phageparticleswerepelletedandsubjectedtocesiumchloridedensitygradientpurification.Theresultsareshown;thelargearrowdenotesthecharacteristicl
phage band (the upper bands correspond largely to non-infectious protein debris; data not shown). It can be readily appreciated that stable phage particles were
recovered from all of the preparations, except for the phage that were exclusively complemented by the recombinant gpD-3JCLI4 protein. This suggests that the
gpD-3JCLI4proteinfailedtosupporttheassemblyofstablephageparticlesandthatthisdeficiencycouldbeovercomebyco-expressionofthewild-typegpDprotein
(as in the 3JCLI4 DUAL and CDF3JCLI4 DUAL preparations).
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were complemented using wild-type gpD alone), although it
was noted that the use of the pBR-based gpD fusion constructs
resulted in somewhat lower titers of the mosaic phage, as
compared to their CDF-based counterparts (compare titers
for 3JCLI4 DUAL with those for CDF3JCLI4 DUAL;
Figure 3). The reasons for this are uncertain, but may relate
to differences in plasmid copy number and/or efﬁciency of
protein expression from the different plasmid backbones.
An aliquot (1 · 10
9 PFU) of each of these phage prepara-
tions was extracted, separated on a 20% SDS–PAGE gel, and
subjected to immunoblot analysis using the rabbit polyclonal
antiserum against gpD. As expected, the phage preparations
that were derived from lysogens that had been cotransformed
with wild-type and recombinant gpD expression plasmids con-
tained two distinct forms of gpD—consistent with their being
gpD-mosaic phages (compare results for gpD wild-type to
those for the other constructs shown in Figure 4). It was
also noted that use of the pBR-based gpD fusion constructs
resulted in slightly greater levels of recombinant gpD into the
phage particles, as compared to the CDF-based plasmids
(compare results for 3JCLI4 DUAL with those for
CDF3JCLI4 DUAL; Figure 4).
DISCUSSION
Phage display technology allows for the presentation of for-
eign peptides and proteins on the surface of bacteriophage
(6,21,51). This technology was developed and explored for
the most part with ﬁlamentous phage and it has been shown
that surface expression of receptor-binding peptides or pro-
teins can result in phage binding to mammalian cells and,
in some cases, in phage internalization (14–16,23–25,35,
36,52,53). When such phage contain mammalian expression
cassettes, this can result in expression of encoded genes within
the target cells of interest (14,15,23–25,35,37). These
Figure3.Co-expressionof3JCLI4-gpDandwild-typegpDyieldsinfectiousphageparticles.LysogensofTOP10cellscontaininggpD-deficientlD1180(Luc)were
transformedwithplasmidvectorsencodingeitherwild-typegpDalone(gpD;seeFigure1A)orwithtwoplasmids,correspondingtotheconstructsshowninFigure1C
(3JCLI4 DUAL) or Figure 1D (CDF3JCLI4 DUAL); these paired constructs permitted the co-expression of wild-typeand recombinant gpD in the same E.coli host
cell. Followinglysogen induction, CsCl-banding and dialysis,purified phage particles were titered on LE392E.coli host cells.Results shownrepresent phage titers
fromthreeseparatephagepreparations;noappreciableamountsofinfectiousphagewererecoveredfromlysogensthatexpressedonlythegpD-3JCLI4fusionprotein
(Figure 1B).
Figure 4. Co-expression of 3JCLI4-gpD and wild-type gpD results in the
generation of mosaic phage particles. Lysogens of TOP10 cells containing
gpD-deficientlD1180(Luc)weretransformedwithplasmidvectorsencoding
either wild-type gpD alone (gpD) or with two plasmids that permitted the co-
expression of wild-type and recombinant gpD in the same E.coli host cell
(3JCLI4 DUAL and CDF3JCLI4 DUAL; see Figures 1–3). Following lysogen
induction, CsCl-banding and dialysis, purified phage particles were titered on
LE392 E.coli host cells. A total of 1 · 10
9 PFU of each preparation was then
loaded on a 20% SDS–PAGE gel and phage protein content was examined by
immunoblotanalysis,usingarabbitpolyclonalantiserumdirectedagainstgpD.
Theresultsshowincorporationofwild-typegpD( 12kDa)intoallofthephage
preparations (as expected), as well as inclusion of recombinant gpD-3JCLI4
( 23 kDa) in those preparations that were generated from lysogens that had
been co-transformed with both wild-type and recombinant gpD expression
vectors. It is also apparent that lower levels of recombinant gpD-3JCLI4 were
incorporated when the recombinant protein was expressed from a CDF-origin
containing construct, as compared to a pBR322-based plasmid.
PAGE 5 OF 7 Nucleic Acids Research, 2005, Vol. 33, No. 18 e160advances have led to the proposed use of bacteriophage as
gene delivery vehicles.
The development of recombinant l phage vectors capable
of efﬁciently transducing mammalian cells is also likely to
require the expression of speciﬁc cell-targeting ligands on the
phage surface, as well as additional modiﬁcations to the phage
coat that may facilitate cell uptake or phage uncoating.
However, a number of technical limitations must be circum-
vented before this, will be possible. Among these is the fact
that some recombinant gpD proteins cannot support phage
assembly/stability, as shown here for gpD-3JCLI4. In an effort
to address this problem, we have developed a plasmid-based
dual expression system that permits the generation of mosaic
phage particles that incorporate a mixture of both wild-type
and recombinant gpD. This approach is conceptually analog-
ous to the mosaic gene VIII vectors that have been developed
for the surface display of large proteins on the major capsid
proteinofﬁlamentousphage (7,48–50).CreationofthesegpD-
mosaic lambda phage particles is possible through the use of
E.coli host cells that contain (i) an inducible, gpD-deﬁcient
l lysogen and (ii) two independently selectable plasmid
vectors that express wild-type gpD and the recombinant
gpD protein of interest, respectively.
The development of this ﬂexible gpD co-expression system
is expected to substantially facilitate future development of
lambda phage display vectors, as well as gene transfer vectors
based on this bacteriophage.
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